Nivolumab is given as an intravenous (IV) infusion, typically over 30 minutes. You receive it at an infusion center or hospital, where a nurse connects an IV line and delivers the medication directly into your bloodstream. Most people receive treatment either every 2 weeks or every 4 weeks, depending on the dose their oncologist selects.
What Happens During the Infusion
Each infusion takes about 30 minutes. The medication flows through an IV line fitted with a special filter that removes any tiny particles before they enter your body. You’ll sit in a chair or recline during the process, and a nurse will monitor you throughout. Many infusion centers allow you to read, use your phone, or have someone sit with you while the drip runs.
Although no mandatory observation period is specified in the prescribing label, most treatment centers will keep you for a short time afterward, particularly during your first few sessions, to watch for any immediate reactions before sending you home.
Dosing Schedules for Adults
Adults receive one of two flat-dose options: 240 mg every 2 weeks or 480 mg every 4 weeks. “Flat dose” means every adult gets the same amount regardless of body weight. The choice between the two schedules often comes down to convenience and what works best with the rest of your treatment plan. Both deliver equivalent drug exposure over time, so the 4-week option simply consolidates two smaller doses into one larger, less frequent visit.
Dosing for Adolescents and Children
Younger patients who weigh 40 kg (about 88 pounds) or more in the U.S. receive the same flat doses as adults: 240 mg every 2 weeks or 480 mg every 4 weeks. Those weighing less than 40 kg get a weight-based dose instead, calculated at 3 mg per kilogram every 2 weeks or 6 mg per kilogram every 4 weeks. In the European Union, the weight cutoff for switching to flat dosing is slightly higher, at 50 kg.
Combination With Ipilimumab
For certain cancers, nivolumab is given alongside another immunotherapy drug, ipilimumab. In this combination, nivolumab is infused first. After that infusion finishes, you wait at least 30 minutes before the ipilimumab drip begins on a separate, fresh IV line. The combination phase typically lasts four treatment cycles, after which you continue on nivolumab alone.
During the combination phase, the dosing and schedule can differ from nivolumab monotherapy, so each cycle may take longer at the infusion center since you’re receiving two drugs back-to-back with a waiting period in between.
Infusion Reactions and What to Watch For
True allergic or hypersensitivity reactions to nivolumab are uncommon, occurring in roughly 1 to 3 percent of patients. When they do happen, they can include skin flushing, itching, hives, shortness of breath, or a drop in blood pressure. Mild reactions are typically managed with topical treatments and supportive care, and the infusion can sometimes continue at a slower rate.
Severe reactions, though rare, require stopping the infusion immediately. In these cases, treatment may involve high-dose corticosteroids and more intensive support. A severe reaction usually means nivolumab is permanently discontinued, though oncologists may consider switching to a different medication or, in select situations, using a desensitization protocol to attempt retreatment.
It’s worth noting that immune-related side effects, such as skin rashes or inflammation in other organs, can appear days or weeks after an infusion rather than during the session itself. Your care team will discuss what symptoms to report between visits.
Is a Subcutaneous Version Available?
A subcutaneous (under-the-skin) injection form of nivolumab is currently being studied in clinical trials but has not yet received FDA approval. If approved, it would allow the drug to be delivered as a quick injection rather than a 30-minute IV drip, potentially reducing time spent at the infusion center. For now, the IV infusion remains the only approved method of administration.